Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.49 |
| ▸ | NR3C1 known ✓ | P04150 | 1/20 | 0.48 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | RARG | P13631 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5538472 | 0.98 | L3MBTL1 (0.54) | L3MBTL1ALDH1A1MAPK1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL8181153 | 0.97 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1MAPK1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL25310405 | 0.97 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL26287992 | 0.95 | L3MBTL1 (0.51) | L3MBTL1ALDH1A1MAPK1MEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL7758264 | 0.91 | MEN1 (0.49) | L3MBTL1ALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL25681603 | 0.84 | ALDH1A1 (0.56) | L3MBTL1ALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL29375726 | 0.83 | LTA4H (0.48) | L3MBTL1ALDH1A1MAPK1KMT2ALMNA | |
| Hydrochloric Acid SCHEMBL11684413 | 0.83 | ALDH1A1 (0.51) | L3MBTL1ALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL23518457 | 0.83 | ALDH1A1 (0.51) | L3MBTL1ALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL4447797 | 0.83 | LMNA (0.54) | ALDH1A1MEN1KMT2ALMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-11343296-A | — | — | None | — | — | JP | disclosed |
| EP-2967801-B1 | INJECTABLE BIODEGRADABLE BONE MATRIX FOR MULTIPLE MYELOMA LESION AUGMENTATION AND OSTEOPOROSIS | UNIV TOLEDO (US) | 2020-07-08 | — | — | EP | disclosed |
| US-20160030631-A1 | Injectable Biodegradable Bone Matrix for Multiple Myeloma Lesion Augmentation and Osteoporosis | THE UNIVERSITY OF TOLEDO (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2967801-A2 | INJECTABLE BIODEGRADABLE BONE MATRIX FOR MULTIPLE MYELOMA LESION AUGMENTATION AND OSTEOPOROSIS | The University of Toledo (US) | 2016-01-20 | — | — | EP | disclosed |
| CN-105263438-A | Injectable biodegradable bone matrix for multiple myeloma lesion augmentation and osteoporosis | UNIV TOLEDO | 2016-01-20 | — | — | CN | disclosed |
| EP-1894890-B1 | TRANSITION METAL OXIDE NANO-TUBE | JAPAN SCIENCE & TECH AGENCY (JP) | 2014-10-22 | — | — | EP | disclosed |
| WO-2014160232-A2 | INJECTABLE BIODEGRADABLE BONE MATRIX FOR MULTIPLE MYELOMA LESION AUGMENTATION AND OSTEOPOROSIS | THE UNIVERSITY OF TOLEDO (US) | 2014-10-02 | — | — | WO | disclosed |
| US-8586638-B2 | Parakeratosis inhibitor and skin preparation for external use | SHISEIDO COMPANY, LTD (JP) | 2013-11-19 | — | — | US | disclosed |
| CN-102274130-B | Application of n- benzene sulfonyl-l-glutamic acid or saline thereof | SHISEIDO CO LTD | 2013-06-12 | — | — | CN | disclosed |
| US-20120253064-A1 | PARAKERATOSIS INHIBITOR AND SKIN PREPARATION FOR EXTERNAL USE | SHISEIDO COMPANY, LTD. (JP) | 2012-10-04 | — | — | US | disclosed |
| EP-1894890-A1 | TRANSITION METAL OXIDE NANO-TUBE | Japan Science and Technology Agency (JP) | 2008-03-05 | — | — | EP | disclosed |
| US-20070292338-A1 | Transition Metal Oxide Nano-Tube | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-12-20 | — | — | US | disclosed |
| US-20070225380-A1 | Parakeratosis Inhibitor and Skin Preparation for External use | SHISEIDO COMPANY LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| CN-1886114-A | Parakeratosis inhibitor and composition for external use on skin | SHISEIDO CO LTD (JP) | 2006-12-27 | — | — | CN | disclosed |
| EP-1688126-A1 | PARAKERATOSIS INHIBITOR AND EXTERNAL COMPOSITION FOR SKIN | SHISEIDO COMPANY LIMITED (JP) | 2006-08-09 | — | — | EP | disclosed |
| US-6030640-A | Oligoglycine compound, fibrous microtube of oligoglycine compound and process of producing fibrous microtube | DIRECTOR-GENERAL OF AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2000-02-29 | — | — | US | disclosed |
| JP-H11343296-A | DOUBLE-HEADED LIPID CONTAINING C END OF OLIGOPEPTIDE CHAIN | AGENCY OF IND SCIENCE & TECHNOL | 1999-12-14 | — | — | JP | disclosed |
| US-5910565-A | PEPTIDE LIPID WHICH WILL FORM MOLECULAR ASSEMBLIES (WHICH ARE STABLE IN A DRIED STATE) WHEN ALLOWED TO STAND FOR TWO TO THREE WEEKS IN AN AQUEOUS SOLUTION | DIRECTOR-GENERAL OF AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 1999-06-08 | — | — | US | disclosed |
| US-5876748-A | DRUG DELIVERY | DIRECTOR-GENERAL OF AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 1999-03-02 | — | — | US | disclosed |
| US-4092304-A | OLIGOPEPTIDE; ANALGESICS, ANTIDIARRHEAL AGENTS, NON-ADDICTING NARCOTIC ANTAGONISTS | G. D. SEARLE & CO. (US) | 1978-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030631-A1 | Injectable Biodegradable Bone Matrix for Multiple Myeloma Lesion Augmentation and Osteoporosis | SOST, COL2A1, COL1A1 | GLA 39/4885NR3C1 2789/4885OPRK1 2731/4885 |
| US-20120253064-A1 | PARAKERATOSIS INHIBITOR AND SKIN PREPARATION FOR EXTERNAL USE | CUTA, HPN, PRSS1 | GLA 53/4885NR3C1 4602/4885OPRK1 4617/4885 |
| US-20070225380-A1 | Parakeratosis Inhibitor and Skin Preparation for External use | CUTA, HPN, DNPEP | GLA 164/4885NR3C1 4791/4885OPRK1 4322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.